CTLA4 and graft versus host disease: This interest was not only in autoimmune diseases but also in transplantation, like using abatacept in the prevention of GVHD in SCT and using belatacept, a second-generation CTLA4-Ig, to prevent graft rejection in solid organ transplants (68).